Sarepta Therapeutics Inc
SRPT18.500USD
+1.470+8.63%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.94BMarket Cap
LossP/E TTM
More Details of Sarepta Therapeutics Inc Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Sarepta Therapeutics Inc Info
Ticker SymbolSRPT
Company nameSarepta Therapeutics Inc
IPO dateJun 04, 1997
CEOIngram (Douglas S)
Number of employees1372
Security typeOrdinary Share
Fiscal year-endJun 04
Address215 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16172744000
Websitehttps://www.sarepta.com/
Ticker SymbolSRPT
IPO dateJun 04, 1997
CEOIngram (Douglas S)
Company Executives of Sarepta Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+32596.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
929.39K
+539084.00%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
196.90K
-4582.00%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
176.27K
-13187.00%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.04K
-158.00%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
29.15K
+3720.00%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-537.00%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-16832.00%
Dr. M. Kathleen Behrens, Ph.D.
Dr. M. Kathleen Behrens, Ph.D.
Independent Chairwoman of the Board
Independent Chairwoman of the Board
--
--
Dr. Stephen L. Mayo, Ph.D.
Dr. Stephen L. Mayo, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+32596.00%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
929.39K
+539084.00%
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
196.90K
-4582.00%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
176.27K
-13187.00%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.04K
-158.00%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
29.15K
+3720.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
PMO Products
238.54M
59.73%
ELEVIDYS
131.50M
32.93%
collaboration and other
29.31M
7.34%
By RegionUSD
Name
Revenue
Proportion
United States
340.63M
85.29%
Rest of World
29.41M
7.37%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
PMO Products
238.54M
59.73%
ELEVIDYS
131.50M
32.93%
collaboration and other
29.31M
7.34%
Shareholding Stats
Updated: Fri, Nov 21
Updated: Fri, Nov 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.19%
BlackRock Institutional Trust Company, N.A.
11.00%
State Street Investment Management (US)
5.06%
Two Sigma Investments, LP
3.91%
Barry (Richard J)
3.07%
Other
65.77%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.19%
BlackRock Institutional Trust Company, N.A.
11.00%
State Street Investment Management (US)
5.06%
Two Sigma Investments, LP
3.91%
Barry (Richard J)
3.07%
Other
65.77%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.96%
Investment Advisor/Hedge Fund
21.69%
Hedge Fund
15.79%
Research Firm
6.02%
Individual Investor
5.17%
Pension Fund
1.47%
Sovereign Wealth Fund
0.90%
Bank and Trust
0.68%
Family Office
0.07%
Other
8.26%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1030
90.74M
86.59%
-19.50M
2025Q3
1019
84.30M
80.53%
-21.85M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
10.79M
10.3%
+146.31K
+1.37%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
11.52M
11%
+1.68M
+17.10%
Sep 30, 2025
State Street Investment Management (US)
5.30M
5.06%
+609.88K
+12.99%
Sep 30, 2025
Two Sigma Investments, LP
4.10M
3.91%
-51.63K
-1.24%
Sep 30, 2025
Barry (Richard J)
3.21M
3.07%
+32.60K
+1.02%
May 16, 2025
Erste Asset Management GmbH
2.69M
2.56%
+1.06M
+65.65%
Sep 30, 2025
Renaissance Technologies LLC
2.65M
2.53%
+2.03M
+324.38%
Sep 30, 2025
abrdn Inc.
1.98M
1.89%
+740.36K
+59.59%
Sep 30, 2025
UBS Financial Services, Inc.
1.98M
1.89%
+1.50M
+315.87%
Sep 30, 2025
D. E. Shaw & Co., L.P.
2.01M
1.92%
-3.05M
-60.33%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
3.74%
First Trust NYSE Arca Biotechnology Index Fund
3.65%
Invesco Biotechnology & Genome ETF
3.49%
Invesco S&P SmallCap Health Care ETF
1.44%
Global X Genomics & Biotechnology ETF
1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
1.32%
Virtus LifeSci Biotech Products ETF
1.03%
State Street SPDR S&P Biotech ETF
1.03%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Health Care Alphadex Fund
0.51%
View more
iShares Neuroscience and Healthcare ETF
Proportion3.74%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.65%
Invesco Biotechnology & Genome ETF
Proportion3.49%
Invesco S&P SmallCap Health Care ETF
Proportion1.44%
Global X Genomics & Biotechnology ETF
Proportion1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.32%
Virtus LifeSci Biotech Products ETF
Proportion1.03%
State Street SPDR S&P Biotech ETF
Proportion1.03%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.63%
First Trust Health Care Alphadex Fund
Proportion0.51%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
